MiR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2

International Journal of Molecular Medicine

Volumn 32, Issue 3, 2013, Pages 593-598

  Qiu, Tianzhu ^a   Zhou, Li ^a   Wang, Tongshan ^a   Xu, Jing ^a   Wang, Jian ^a   Chen, Wenjiao ^a   Zhou, Xin ^a   Huang, Zebo ^a   Zhu, Wei ^a   Shu, Yongqian ^a   Liu, Ping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Cisplatin resistance; Lung cancer; MiR 503

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 503; PROTEIN BCL 2; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84880416262     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1439     Document Type: Article

References (39)

1. Szakács G, Paterson JK, Ludwig JA, et al: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
2. Zhang K, Mack P and Wong KP: Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 12: 871-882, 1998.
3. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
4. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
5. Fojo T: Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 10: 59-67, 2007.
6. Glasspool RM, Teodoridis JM and Brown R: Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092, 2006.
7. Sharma SV, Lee DY, Li B, et al: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80, 2010.
8. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
9. Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789, 2010.
10. Chen GQ, Zhao ZW, Zhou HY, et al: Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 27: 406-415, 2010.
11. Bourguignon LY, Spevak CC, Wong G, et al: Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284: 26533-26546, 2009.
12. Li Y, Li W, Yang Y, et al: MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 1286: 13-18, 2009.
13. Xu K, Liang X, Cui D, et al: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog 52: 70-78, 2013.
14. Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123: 372-379, 2008.
15. Chen J, Tian W, Cai H, et al: Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 29: 2527-2534, 2012.
16. Zhou J and Wang W: Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol 104: 278-283, 2011.
17. Lu YC, Chen YJ, Wang HM, et al: Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila) 5: 665-674, 2012.
18. Özata DM, Caramuta S, Velázquez-Fernández D, et al: The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 18: 643-655, 2011.
19. Corbetta S, Vaira V, Guarnieri V, et al: Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 17: 135-146, 2010.
20. Zhao JJ, Yang J, Lin J, et al: Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 25: 13-20, 2009.
21. Cui YH, Xiao L, Rao JN, et al: miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies. Mol Biol Cell 23: 151-162, 2012.
22. Jiang Q, Feng MG and Mo YY: Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer 9: 194, 2009.
23. Cheng G, Sun S, Wang Z and Jin S: Investigation of the interaction between the miR-503 and CD40 genes in irradiated U937 cells. Radiat Oncol 7: 38, 2012.
24. Zhu W, Zhu D, Lu S, et al: miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 29: 384-391, 2012.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
26. Yamaue H, Tanimura H, Noguchi K, et al: Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay. Br J Cancer 66: 794-799, 1992.
27. Yamaue H, Tani M, Onishi H, et al: Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 25: 366-372, 2002.
28. Wang S, Yang D and Lippman ME: Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 30 (Suppl 16): S133-S142, 2003.
29. Reed JC: Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Prac Oncol 3: 388-398, 2006.
30. Tanida S, Mizoshita T, Ozeki K, et al: Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012: 862879, 2012.
31. Beale PJ, Rogers P, Boxall F, et al: BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 82: 436-440, 2000.
32. Yu L and Wang Z: Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. J Huazhong Univ Sci Technolog Med Sci 24: 151-153, 2004.
33. Dong Z and Wang J: Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem 279: 9215-9221, 2004.
34. Williams J, Lucas PC, Griffith KA, et al: Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295, 2005.
35. Zhu W, Shan X, Wang TS, et al: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127: 2520-2529, 2010.
36. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): S4-S11, 2005.
37. Li D, Zhao Y, Liu C, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res17: 1722-1730, 2011.
38. Saito Y, Liang G, Egger G, et al: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443, 2006.
39. Datta J, Kutay H, Nasser MW, et al: Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68: 5049-5058, 2008.